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Cardiac Resynchronization Therapy 
in Heart Failure Management
Hilman Zulkifli Amin, Siska Suridanda Danny
Heart failure (HF) is a worldwide health problem with high prevalence 
rate. The prevalence is over 23 million worldwide. It is a chronic disease 
characterized by the inability of the heart to pump an adequate amount of 
blood to achieve the demand of the different organ systems and/or doing 
so at increased filling pressures. Despite many recent advances in medi-
cation, the rate of people with HF is rising. This health challenges need 
to be answered properly. One of the new important treatment for HF is 
cardiac resynchronization therapy (CRT). Many patients with HF also have 
an abnormality of the heart’s electrical system resulting in asynchronous 
contraction pattern of heart muscle.
The ultimate goal of CRT is to restore synchrony of the heart rhythm in HF 
patients. CRT implantation in heart failure patients with proper indications 
like wide QRS complexes, low left ventricular ejection fraction (LVEF), and 
left bundle branch block (LBBB) has been proved to reduce morbidity, 
mortality, and also improve symptoms and quality of life (QoL).
(J Kardiol Indones. 2015;36:227-36)
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Gagal jantung (GJ) merupakan masalah kesehatan utama dunia dengan tingkat prevalensi yang tinggi. Di seluruh dunia, 
prevalensi GJ mencapai 23 juta orang. GJ merupakan penyakit kronik dengan karakteristik berupa ketidakmampuan jantung 
dalam memompa darah untuk memenuhi kebutuhan sistem organ dan atau diikuti dengan terjadinya peningkatan tekanan isi 
sekuncup. Meskipun telah banyak kemajuan dalam pengobatan GJ, jumlah penderita GJ terus meningkat. Tantangan dalam 
dunia kesehatan ini perlu segera dipenuhi. Salah satu terapi baru dan penting dalam penanganan GJ ialah terapi resinkronisasi 
jantung (TRJ). Terdapat banyak pasien GJ juga mengalami abnormalitas sistem konduksi jantung yang menyebabkan terjadinya 
ketidaksinkronan pola kontraksi otot jantung.
Tujuan utama dari TRJ ialah mengembalikan sinkronisasi ritme jantung pada pasien GJ. Pemasangan TRJ pada pasien GJ 
dengan indikasi yang tepat dan sesuai seperti kompleks QRS yang lebar, ejeksi fraksi ventrikel kiri yang rendah, dan blok 
berkas cabang kiri telah terbukti dapat menurunkan angka morbiditas, mortalitas, dan juga meningkatkan kualitas hidup 
serta memperbaiki gejala.
(J Kardiol Indones. 2015;36:227-36)
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Heart failure (HF) is a chronic disease characterized by the inability of the heart to pump an adequate amount of blood to achieve the demand of the different organ 
systems and/or doing so at increased filling pressures.1 
HF caused by the weakening of the heart muscle. It is 
most commonly caused by irreversible damage from 
coronary artery disease, but may also be result of viral 
infections, genetic factors, or toxins.2 
HF is a worldwide health problem with high 
prevalence rate. The prevalence is over 23 million 
worldwide.3 This disease carries substantial risk of 
morbidity and mortality. Over 2.4 million patients are 
hospitalized and nearly 300,000 deaths annually are 
directly attributable to HF. There is a dramatic increase 
in the prevalence of HF. The growing prevalence 
of HF might reflect increasing incidence, an aging 
population, improvements in the treatment of acute 
cardiovascular disease and HF, or combination of 
these factors. Since then, medications are the mainstay 
therapy for patients with HF.
Medications help rid the body extra fluid, 
strengthen the heart’s contraction, and ease the heart’s 
workload by relaxing the blood vessels and reducing 
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of this electrical delay on an electrocardiogram (ECG) 
is widening of the QRS complex.
Cardiac Resynchronization Therapy 
(CRT)
The ultimate goal of CRT is to restore synchrony 
of the heart rhythm in HF patients.  It is a unique 
type of cardiac pacemaker.5 Pacemakers usually 
being used to prevent symptoms associated with 
symptomatic slow heart rates. The patient’s heart rate 
is continuously monitored by the pacemaker. The 
heart rate is stimulated by the pacemaker by delivering 
a tiny electrical charge when necessary.3 Common 
pacemakers have 2 leads, one in the right atrium and 
one in the right ventricle, in order to keep the normal 
pump function relationship between bottom and 
top of the heart. These leads are connected to a pulse 
generator placed under the skin in the upper chest. 
CRT is a specialized type of pacemakers, that 
have a third lead which is positioned in a vein on the 
outer surface of the left ventricle, in addition to the 
2 leads used by common pacemakers.3,5 This allows 
a synchronous pumping action of left and right 
ventricle. 
There are two types of CRT, a CRT pacemaker 
and a combination CRT pacemaker with defibrillation 
therapy (CRT-D).5 Both help to coordinate the heart 
pumping action and improve blood flow. In CRT-D, it 
also has the ability to detect and treat malignant heart 
rhythms, which some individuals with a damaged heart 
muscle may be at risk for developing. The decision of 
which device to use depends on the physician. 
the resistance to pumping blood.3 Despite many recent 
advances in medication, the rate of people with HF 
is rising. This health challenges need to be answered 
properly. One of the new important treatment for 
HF is cardiac resynchronization therapy (CRT). 
Many patients with HF also have an abnormality of 
the heart’s electrical system resulting in asynchronous 
contraction pattern of heart muscle.
Heart Electrical System Conduction In 
Hf
The normal heart rhythm is originated by an electrical 
signal from a region of the right atrium (RA) known 
as the sinoatrial or SA node. After that, the electrical 
signal run through both atria and make them pump 
blood into the ventricles.3 The atrioventricular node or 
AV node, then is reached by an electrical signal. The 
signal then spreads through specialized routes called 
the left and right bundle branch branches. Finally, the 
bundle branches stimulate both ventricles to contract 
synchronously. This electrical system conduction is 
important for optimal blood pumping to all over 
body. 
The most common abnormality conduction in 
HF patient is left bundle branch block (LBBB).3 
Because of this block, the right ventricle made an 
earlier contraction than the left ventricle, instead 
of simultaneously. The result is an asynchronous 
contraction of the ventricles. Eventually, cardiac pump 
will lose its efficiency. Almost 40% of HF patients 
have an asynchronous ventricular contraction caused 
by electrical delay, most often LBBB. The appearance 
Figure 1. LBBB and Improvement of Conduction System by CRT4
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Indications and Benefits of CRT in 
Heart failure Management
Many conclusive evidences of CRT benefits in HF 
from several randomized clinical trials (RCTs).6 The 
inclusion criteria used in the most RCTs was, New York 
Heart Association (NYHA) functional class III-IV in 
sinus rhythm (SR), low left ventricular ejection fraction 
(LVEF) < 35%, and duration of QRS interval > 120 
ms. The Cardiac Resynchronization in Heart Failure 
(CARE-HF) trials with 813 patients evaluated all-cause 
mortality, hospitalization, NYHA functional class, 
and quality of life (QoL).6,7 This study was double-
blinded and randomized trial. The result was CRT 
proved to reduce all-cause mortality, hospitalization, 
improved NYHA functional class, and QoL. Other 
study showing similar result was Comparison of 
Medical Therapy, Pacing, and Defibrillation in Heart 
Failure (COMPANION) trial. This study even has 
larger subjects which was 1520 patients.6,8 The result 
was also the same that CRT could reduced all-cause 
mortality or hospitalization. Other studies like 
Multisite Stimulation in Cardiomyopathy (MUSTIC), 
Pacing Therapies in Congestive Heart Failure (PATH-
CHF), and Multicenter InSync Randomized Clinical 
Evaluation (MIRACLE) trials also showed superiority 
of CRT in HF paients.6,9-11 These studies proved that 
CRT could improved QoL, NYHA functional class, 
6-minutes walk distance (6MWD), LVEF, and peak 
VO2. 
However, in accordance to the low number of 
subjects enrolled in RCTs, the evidence in HF patients 
with NYHA functional class IV was limited (from 7 
to 15%).6 Ambulatory HF patients functional class 
IV showed a significant reduction in the combined 
primary endpoint of time to all-cause mortality 
and hospitalization as shown in a sub-study of 
COMPANION trial.6,8 The summary of the RCTs of 
CRT benefit in HF patients with NYHA functional 
class III-IV, sinus rhythm, poor left ventricular ejection 
fraction (LVEF), and prolonged QRS interval (>120 
ms) will be shown on the table below.
Other topic related to the CRT benefit in HF 
patients was the impact of QRS duration on the efficacy 
of CRT. Subgroup analysis, in a recent meta-analysis 
from COMPANION and CARE-HF trials, evaluating 
the impact of QRS duration on the efficacy of CRT, 
has shown that, in NYHA functional class III-IV HF 
patients, CRT significantly reduced all-cause mortality 
or hospitalization in patients with QRS duration > 150 
ms.6-8 The effect and benefit of CRT declined with 
shorter QRS duration. These studies also supported by 
Multicenter Automatic Defibrillator Implantation Trial 
with Cardiac Resynchronization Therapy (MADIT-CRT) 
trial.6,12 It showed that patients with a QRS duration 
> 150 ms, has a most benefit effect from CRT and 
suggested that it might not effective in patients with QRS 
< 150 ms. In addition, most patients in the RCTs had 
LBBB morphology, which was associated, with a more 
pronounced benefit, compared with non-LBBB patients. 
It was shown in the MADIT-CRT, Resynchronization-
Defibrillation for Ambulatory Heart Failure (RAFT), 
and Resynchronization Reverses Remodelling in Systolic 
Left Ventricular Dysfunction (REVERSE) trials, and a 
meta-analysis of COMPANION, CARE-HF, MADIT-
CRT, and RAFT.6,12-14 Patients with complete LBBB, 
showed a greater benefit on the composite of morbidity 
and mortality from CRT, compared with patients with 
non-specific IVCD or RBBB.6 However, patients with 
LBBB had longer QRS duration, and therefore analyses 
by morphology may be confounded by QRS duration. 
On the other hand, the MADIT-CRT trial showed 
that non-LBBB patients did not derive clinical benefit 
from CRT (statistically not significant 24% increased 
risk).6,12 Other trials also showed consistent results that 
indicated clinical benefit of CRT in LBBB patients.5 
Based on this evidence, current class I recommendations 
were restricted to patients with complete LBBB. The 
relationship between QRS duration and morphology 
requires further research. 
Figure 2. CRT Lead Placement4
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Table 1. Summary of Randomized Clinical Trials6 (With permission of Oxford University Press (UK) (c) European Society of 
Cardiology, www.escardio.org) Evaluating CRT in HF patients and Sinus Rhythm 
Trial No. 
Patients
Design NYHA 
Functional 
Class
LVEF QRS Primary End-
points
Secondary End-
points
Main Findings
MUSTIC-SR 58 Single-blinded, 
crossover, 
randomized 
CRT vs OMT, 
6 months
III <35% >150 
ms
6MWD NYHA class, 
QoL,
peak VO2LV 
volumes,
MR hospitaliza-
tions,
mortality
CRT-P improved 
6MWD,
NYHA class, 
QoL, peak VO2,
reduced LV vol-
umes and MR
and reduced 
hospitalizations
PATH-CHF 41 Single-blinded, 
crossover, 
randomized RV 
vs LV vs BiV, 12 
months
III-IV NA >150 
ms
Peak VO2,
6MWD
NYHA class, QoL
hospitalizations
CRT-P improved 
NYHA class,
QoL and 6MWD 
and reduced
hospitalizations
MIRACLE 453 Double-blinded,
randomized 
CRT vs.
OMT, 6 months
III-IV <35% >130 
ms
NYHA class,
6MWD , QoL
Peak VO2 
LVEDD,
LVEF, MR
clinical composite
response
CRT-P improved 
NYHA class,
QoL and 6MWD 
and reduced
LVEDD, MR and 
increased LVEF
MIRACLE-ICD 369 Double-blinded,
randomized
CRT-D vs. 
ICD,
6 months
III-IV <35% >130 
ms
NYHA class,
6MWD , QoL
Peak VO2
LVEDD, LVEF, 
MR
clinical composite
response
CRT-D improved 
NYHA class,
QoL, peak VO2
CONTAK-CD 490 Double-blinded
randomized
CRT-D vs. 
ICD,
6 months
II-IV <35% >120 
ms
NYHA class,
6MWD , QoL
LV volume, LVEF
composite of
mortality, VT/VF,
hospitalizations
CRT-D improved 
6MWD,
NYHA class, 
QoL,
reduced LV vol-
ume and
increased LVEF
MIRACLE-
ICD II
186 Double-blinded,
randomized
CRT-D vs. 
ICD,
6 months
II <35% >130 
ms
Peak VO2 VE/VCO2, 
NYHA,
QoL, 6MWD, 
LV
volumes and EF,
composite clinical
endpoint
CRT-D improved 
NYHA,
VE/CO2 and 
reduced
LV volumes and 
improved LVEF
COMPANION 1520 Double-blinded
randomized
OMT vs. 
CRT-P / or
vs. CRT-D,
15 months
III-IV <35% >120 
ms
All-cause
mortality or
hospitalization
All-cause mortal-
ity,
cardiac mortality
CRT-P and 
CRT-D reduced
all-cause mortal-
ity or
hospitalization
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CARE-HF (Cardiac Resynchronization-Heart Failure); CONTAK-CD (CONTAK-Cardiac Defibrillator); COMPANION (Comparison 
of Medical Therapy, Pacing and
Defibrillation in Heart Failure); CRT-D (Cardiac Resynchronization therapy with Defibrillator); CRT-P (Cardiac Resynchronization 
Therapy Pacemaker); LV (Left Ventricular; LVEDD (Left Ventricular End-Diastolic Dimension); LVEF (Left Ventricular Ejection 
Fraction); LVESV (Left Ventricular End-Systolic Volume); MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with 
Cardiac Resynchronization Therapy); MIRACLE (Multicenter InSync Randomized Clinical Evaluation); MIRACLE-ICD (Multicenter 
InSync Implantable Cardioverter Defibrillator trial); MR (Mitral Regurgitation); MUSTIC (Multisite Stimulation in Cardiomyopathies); 
No (Number of Patients) ; NYHA (New York Heart Association); PATH-CHF (Pacing Therapies in Congestive Heart Failure Trial); QoL( 
Quality of Life Score); RAFT (Resynchronization Defibrillation for Ambulatory Heart Failure Trial); VE/VCO2 (Minute Ventilation/
Minute Volume Carbondioxide Production); VF (Ventricular Fibrillation); VO2 (Volume of Oxygen); VT (Ventricular Tachycardia; 
6MWD (6-min Walk Distance)
CARE-HF 813 Double-blinded
randomized
OMT vs. 
CRT-P
29.4 months
III-IV <35% >120 
ms
All-cause
mortality or
hospitalization
All-cause mortal-
ity,
NYHA class, QoL
CRT-P reduced 
all-cause
mortality and 
hospitalization
and improved 
NYHA class and
QoL
REVERSE 610 Double-blinded,
randomized
CRT-ON vs.
CRT-OFF,
12 months
I-II <40% >120 
ms
% worsened
by clinical
composite
endpoint
LVESV index,
heart failure
hospitalizations 
and
all-cause mortality
CRT-P/CRT-D 
did not change
the primary end-
point and did
not reduce all-
cause mortality
but reduced 
LVESV index and
heart failure hos-
pitalizations
MADIT-CRT 1820 Single-blinded,
randomized
CRT-D vs. 
ICD,
12 months
I-II <30% >130 
ms
All-cause
mortality or
heart failure
hospitalizations
All-cause mortal-
ity
and LVESV
CRT-D reduced 
the endpoint
heart failure hos-
pitalizations or
all-cause mortality 
and LVESV.
CRT-D did not 
reduced
all-cause mortality
RAFT 1798 Double-blinded,
randomized 
CRT-D
vs. ICD
40 months
I-II <30% >120 
ms
All-cause
mortality or
heart failure
hospitalizations
All-cause mortal-
ity
and cardiovascular
death
CRT-D reduced 
the endpoint
all-cause mortality 
or heart
failure hospitaliza-
tions. In
NYHA III, 
CRT-D only 
reduced signifi-
cantly all-cause 
mortality
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Table 2. Indications for CRT in HF Patients and Sinus 
Rhythm6 (With permission of Oxford University Press (UK) 
(c) European Society of Cardiology, www.escardio.org)
Recommendations Classa Levelb
1) LBBB with QRS
duration >150 ms.
CRT is recommended in
chronic HF patients and 
LVEF
≤35% who remain in 
NYHA
functional class II, III and
ambulatory IV despite 
adequate
medical treatment.d
I A
2) LBBB with QRS
duration 120–150 ms.
CRT is recommended in
chronic HF patients and 
LVEF
≤35% who remain in 
NYHA
functional class II, III and
ambulatory IV despite 
adequate
medical treatment.d
I B
In HF patients with NYHA functional class 
I-II, sinus rhythm, LVEF < 30-40% and QRS 
duration > 120-130 ms, four RCTs which were 
MADIT-CRT, RAFT, REVERSE, and Multicenter 
InSync Implantable Cardioverter Defibrillator 
(MIRACLE-ICD) trials have demonstrated that 
CRT improves LV function, all-cause mortality and 
HF hospitalizations.6,12-15 However, improvement in 
functional status or quality of life among patients 
randomized to CRT were not too significant. Most 
patients enrolled had NYHA functional class II; only 
15% in Resynchronization Reverses Remodelling in 
Systolic Left Ventricular Dysfunction (REVERSE) 
and 18% in Multicenter Automatic Defibrillator 
Implantation Trial with Cardiac Resynchronization 
Therapy (MADIT-CRT) were in NYHA functional 
class I. CRT did not reduce all-cause mortality of 
HF events among NYHA functional class I patients. 
Therefore, the recommendation is restricted to patients 
in NYHA functional class II.  
Finally, there is no evidence of benefit in patients 
with HF and QRS < 120 ms. In the Cardiac 
Resynchronization Therapy In Patients with Heart 
Failure and Narrow QRS (RethinQ) trial, CRT did not 
improve peak oxygen consumption (primary endpoint) 
or QoL in the subgroup of patients with QRS < 120 
ms and evidence of echocardiography dysscynhrony.6,16 
Figure 3. Benefit Scale of CRT Based on Clinical Factors6 (With permission of Oxford University 
Press (UK) (c) European Society of Cardiology, www.escardio.org)
Highest Benefit Wider QRS, left bundle
branch block, females,
cardiomyopathy
Males,Ischemic Cardiomyopathy
Lowest Benefit Narrower QRS, non-left bundle
branch block
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Other randomized and double-blind study named 
Evaluation of Resynchronization Therapy for Heart 
Failure in Patients with a QRS Duration Lower Than 
120 ms (LESSER-EARTH) was prematurely stopped 
due to safety concerns.6,17 
3) Non-LBBB with QRS
duration >150 ms.
CRT should be considered 
in
chronic HF patients and 
LVEF
≤35% who remain in 
NYHA
functional class II, III and
ambulatory IV despite 
adequate
medical treatment.d
IIa B
4) Non-LBBB with QRS
duration 120–150 ms.
CRT may be considered in
chronic HF patients and 
LVEF
≤35% who remain in 
NYHA
functional class II, III and
ambulatory IV despite 
adequate
medical treatment.d
IIb B
5) CRT in patients with
chronic HF with QRS 
duration
<120 ms is not recom-
mended
III B
CRT (Cardiac Resynchronization Therapy); HF (Heart Fail-
ure); LBBB (Left Bundle Branch Block); LV (Left Ventricular); 
LVEF (Left Ventricular Ejection Fraction); NYHA (New York 
Heart Association)
aClass of recommendation.
bLevel of evidence.
cReference(s) supporting recommendation(s).
dPatients should generally not be implanted during admission 
for acute decompensated HF. In such patients, guideline-indi-
cated medical treatment should be optimized and the patient 
reviewed as an out-patient after stabilization. It is recognized 
that this may not always be possible.
CRT In Heart failure Management 
With Atrial fibrillation (Af)
There are two ways of considering CRT for AF 
patients, first, AF patients with moderate to severe 
HF with a hemodynamic indication for CRT. Second, 
patients with a fast ventricular rate with HF or LV 
dysfunction justifying a strong rate control strategy 
with an AV junction ablation.6
In the first way of considering CRT for AF 
patients were described in Multisite Stimulation in 
Cardiomyopathies (MUSTIC) AF trial.6,18 There was 
a slight but significant improvement in functional 
status in patients with NYHA functional class III, low 
LVEF, AF rhythm, and QRS > 120 ms at 6-month and 
1-year follow-up. In the Ablate and Pace in AF (APAF) 
trial, in the patients with low LVEF, NYHA functional 
class > III, AF rhythm, and QRS > 120 ms, CRT 
significantly reduced the primary endpoint, including 
death, hospitalizations or worsening of HF, as well as 
beneficial effect on LV reverse remodeling.6,19
 Second way, combination of AV junction 
ablation and CRT in uncontrolled heart rate of 
AF patients provided highly efficient rate control, 
regularization of the ventricular response, and also 
improved symptoms.6 Hence, CRT may prevent 
the potential LV asynchrony. The multi-center, 
randomized, and prospective APAF trial with 186 
patients studied about CRT implantation followed 
by AV junction ablation.6,19 During a median follow-
up of 20 months, CRT significantly decreased the 
primary composite endpoint (of death due to HF, 
hospitalization or worsening due to HF) by 63% in 
the overall population. The effects and efficacy of 
CRT were significantly consistent in patients who had 
EF < 35%, NYHA functional class > III, and QRS 
width > 120 ms, thus meeting the requirement of the 
guidelines.
Conclusion
The prevalence of HF is still high. This disease carries 
substantial risk of morbidity and mortality. Over 2.4 
million patients are hospitalized and nearly 300,000 
deaths annually are directly attributable to HF. HF is 
characterized by the inability of the heart to pump an 
adequate amount of blood to achieve the demand of 
the different organ systems and/or doing so at increased 
filling pressures. The most common abnormality 
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conduction in HF patient is left bundle branch block 
(LBBB). Because of this block, the right ventricle made 
an earlier contraction than the left ventricle, instead 
of simultaneously. The result is an asynchronous 
contraction of the ventricles. Eventually, cardiac pump 
will lose its efficiency.. Almost 40% of HF patients have 
an asynchronous ventricular contraction caused by 
electrical delay, most often LBBB. CRT, a specialized 
and unique pacemaker, plays an important new role as 
a novel treatment in HF patients, despite many recent 
advances in medication. HF patients with proper and 
right indications like wide QRS complexes, low left 
ventricular ejection fraction (LVEF), LBBB, SR with 
conduction delay, and permanent AF  have shown 
improvement of symptoms and QoL. Thus, CRT 
have been proven to reduce morbidity and mortality 
in HF patients.
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